Cantor Fitzgerald Maintains Overweight on ACADIA Pharmaceuticals, Raises Price Target to $42
Portfolio Pulse from richadhand@benzinga.com
Cantor Fitzgerald analyst Sarah James maintains an Overweight rating on ACADIA Pharmaceuticals and raises the price target from $36 to $42.
July 17, 2023 | 1:52 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cantor Fitzgerald has maintained an Overweight rating on ACADIA Pharmaceuticals and raised the price target from $36 to $42.
The news is directly related to ACADIA Pharmaceuticals. The Overweight rating and raised price target by Cantor Fitzgerald indicates a positive outlook for the company, which could lead to an increase in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100